Zydus Cadila Seeks Approval to Commence P-III Clinical Study of ZyCoV-D

Shots:

• The company reported that the COVID-19 vaccine is safe, well-tolerated & immunogenic in the P-I/II study & plans to initiate P-III clinical trial in ~30000 volunteers upon receiving necessary approvals
• The P-II study of ZyCoV-D had been conducted in ~1000 healthy adult volunteers as part of the adaptive P-I/II dose-escalation study
• The trial has been reviewed by an independent DSMB & reports have been submitted to CDSCO regularly for the update on safety outcome

Click here ­to­ read full press release/ article | Ref: Zydus Cadila | Image: eHealth Magazine